SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
First Subcutaneous Anti-TNF to Launch with Three Rheumatic Indications Simultaneously and with Novel SmartJect(TM) Autoinjector
HORSHAM, Pa., April 24 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI (golimumab)...
Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- The second approved antibody generated from Medarex's UltiMAb(R) technology platform -
PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced that it will receive a milestone payment of an undisclosed amount from its licensing partner, Centocor O...
New drug shows promising results for psoriatic arthritis Psoriatic
arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor α (anti-TNFα) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic
arthritis. Golimumab is a new human monoclonal antibody that works against...
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Extensive Clinical Development Program Investigating Golimumab in the Treatment of These Diseases Serves as Basis for the Application
HORSHAM, Pa., June 27 /PRNewswire/ -- Centocor, Inc. announced today
that a Biologics License Application (BLA) has been submitted to the U.S.
Food and Drug...
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatologists hopeful that more patients will benefit from increased understanding of therapies for psoriasis
SCHAUMBURG, Ill., May 21 /PRNewswire/ -- The American Academy of
Dermatology (Academy) has released new guidelines of care for the
management of psoriasis and psoriati...
New In-Depth Informative Website Launched for People With Psoriasis and Psoriatic Arthritis
ST ALBANS, England, May 1 /PRNewswire/ -- On the 1st of May 2008, UK
charity, the Psoriasis and Psoriatic
Arthritis Alliance (PAPAA) is
launching its new website http://www.papaa.org under the banner of The
Principal Source of Information for Psoriasis and Psoriatic
PAPAA is provi...
Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis
With the Help of Leading Medical and Lifestyle Experts - Plus TV Style
Expert Stacy London - the National Psoriasis Foundation is Empowering Patients Through Live Seminars and Expanded Web Resources
NEW YORK, Sept. 15 /PRNewswire/ -- People suffering from painful and,
at times, embar...
Largest Survey of Its Kind Finds That People With Psoriasis Are at Risk for Other Medical Conditions
... up to 30 percent of people with psoriasis develop psoriatic
arthritis, which causes pain, swelling and stiffne... with mild psoriasis are just as likely to develop psoriatic
arthritis as those with moderate or severe forms o...oriasis Foundation urges people with psoriasis and psoriatic
arthritis to work with their dermatologists to fin...
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic
arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
ENBREL is indic...
Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement
...e disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic
plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery white appearance. App...
Psoriatic in Medical Technology
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Positive Opinion Recommends Approval of New Anti-TNF Therapy in Three Rheumatic Diseases with Novel SmartJect(TM) Autoinjector
HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNewswire-FirstCall/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP ) announced today that t...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress
COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) inject...
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Golimumab Achieved Primary and Major Secondary Endpoints in the Largest Phase 3 Biologic Trial Completed to Date in Psoriatic
BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic
receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148)
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
...ates, SIMPONI is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; active psoriatic
arthritis in adults, alone or in combination with methotrexate; and active ankylosing spondylitis in adults.
Indications in Canada:
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
...y. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic
arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well est...
AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
...SPRO, over an extended period, has led Daval to
consider Proof of Concept studies in Adhesive Arachnoiditis, treatment
resistant Myasthenia Gravis and psoriatic
AIMSPRO is listed on the Export Only section of the Australian
Therapeutic Goods Registry and is imported into Europe by Biotec Dist...
Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain
...th of relief provided by products that were currently on the market," said RZN Nutraceuticals President Robert Hunt. He should know. Hunt suffers from psoriatic
arthritis, a debilitating form of arthritis. "I've tried them all...the Tiger Balms, the BenGays, the IcyHots...nothing lasts as long as this product....
Scientists Unmask Genetic Markers Associated With Psoriasis
...States, causing sore, itchy patches of red, scaly skin. In many cases psoriasis is not only disfiguring; between 10 and 30 percent of patients develop psoriatic
arthritis, a painful inflammation of the joints. Current treatments, including different types of immunosuppressive agents, aren't always effective, a...
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
...ich usually occur on the scalp, knees, elbows, the abdomen (around the navel) and the genitals. In about a quarter of the cases, psoriasis can lead to psoriatic
arthritis, another inflammatory disease affecting the joints.
While the exact cause of the disease is unknown, it is believed that both genet...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
...monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic
arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and ...
Psoriatic in Medical Dictionary
arthritis is a type of inflammatory arthritis ...ng from the chronic skin condition psoriasis. psoriatic
... Learn more about psoriatic
arthritis , including a description, causes, sym...
... which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis , called psoriatic
plaques, are... Read about psoriasis symptoms, causes, treatment information, medication and ... Patient Discussions: Psoriasis - Effective ...
... is an unpleasant Chronic pain affects an estimated 86 million American adults to some degree. ... 10 Ways to Ease Nighttime Pain . How to Ease psoriatic
Arthritis Symptoms ... Get information about back pain , lower back pain , neck pain , and sciatica, and learn about back pain causes, treatm...
... and the sacroilium in the pelvis, causing eventual fusion of the spine. Provides information about ankylosing spondylitis , Reiter's syndrome, psoriatic
arthritis, spinal arthritis and arthritis associated with inflammatory bowel disease. Ankylosing spondylitis and related disease infor...
Psoriatic in Biological News
Researchers identify 4 genetic hotspots associated with psoriasis
...tic signals from two regulatory elements, TNFAIP3 and TNI1, of TNF-alpha, may be faulty regulating the TNF-alpha induced inflammation of psoriasis and psoriatic
arthritis. Polymorphisms of TNFAIP3 and TNI1 are also associated with two other autoimmune diseases, lupus and rheumatoid arthritis.
The number of...
Scientists uncover new genetic variations linked to psoriasis
...ition is usually characterized by red, scaly skin patches that can be itchy, painful or both. Some 10 to 30 percent of patients with psoriasis develop psoriatic
arthritis, which occurs when inflammation attacks the joints, causing pain and disability.
Both of the new studies looked for common variants in th...
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
...ohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic
arthritis (PsA), ulcerative colitis (UC), pediatric Crohns disease (PCD) an...ssion of structural damage and improving physical function in patients with psoriatic
arthritis. In September 2006, REMICADE was approved for the treatment of ad...
U-M scientists identify major psoriasis susceptibility gene
... and scalp. The disease is disfiguring and can have a negative effect on quality of life. About 25 percent of people with psoriasis eventually develop psoriatic
arthritis, which can be severe.
Unlike diseases caused by a mutation in just one gene, psoriasis is what scientists call a multi-factorial disease...
Psoriatic in Biological Technology
Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Canadian Approval Is World's First Regulatory Approval for SIMPONI
HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/
Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP ) today
announced that Health Canada has granted approval of SIMPONI (TM) (go...
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
New Findings Also Demonstrate Treatment Results in Improvements in Physical Function and Health-Related Quality of Life
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- More than half of patients
receiving every four week subcutaneous injections of golimumab (CNTO 148)
50 mg and 100 mg, an in...
Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
PRINCETON, N.J., March 20 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) today announced that it has received a milestone payment of
an undisclosed amount from its licensing partner, Centocor, Inc., for the
submission of a Marketing Authorization Application to the European
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
HORSHAM, Pa. and KENILWORTH, N.J., March 18 /PRNewswire/ -- Centocor,
Inc. and Schering-Plough Corporation (NYSE: SGP ) announced today that a
Marketing Authorization Application (MAA) has been submitted to the
European Medicines Agency (EMEA) requesting the approval of golimumab (CNTO
Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
Managed Care Organizations Aggressively Control Access to Biologics, According to a New Report from Decision Resources
WALTHAM, Mass., Sept. 10 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds...
Schering-Plough Reports Financial Results for 2009 Second Quarter
...ly, subcutaneous therapy for rheumatoid arthritis, psoriatic
arthritis and ankylosing spondylitis; SIMPONI was ...arly rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, plaque psoriasis, Crohn's disease, pedi...vements in the signs and symptoms in patients with psoriatic
arthritis and ankylosing spondylitis. Separately,...
Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
...atologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in the management of psoriasis and psoriatic
arthritis. This comprehensive report covers treatment approaches for mild, moderate, and severe patients with an emphasis on the evolving use of biol...
Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)
... once-monthly subcutaneous anti-TNF-alpha therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic
arthritis, and active ankylosing spondylitis. The product will be available in two dosing delivery forms: the SIMPONI SmartJect autoinjector and a pr...
BioCis Pharma Starts Phase IIa Trial in Psoriasis
of the general population in the Western countries. Psoriasis may
significantly impair the life quality of the affected subjects, and it may
lead to psoriatic
arthritis, an inflammatory disease affecting the joints.
Existing treatments often have undesirable side effects and do not always
meet the needs of p...
Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style
... serving, and empowering people with psoriasis and psoriatic
arthritis. For more than 35 years, the Psoriasis F... a significant difference in the way psoriasis and psoriatic
arthritis are treated and perceived. We are suppor...rt of increased research funding for psoriasis and psoriatic
arthritis. We also work to educate psoriasis patie...
Psoriatic in Biological Dictionary
...logics are used to treat moderate to severe chronic plaque psoriasis and psoriatic
arthritis. ... Follow The Peters Bieling As They Take You Through The St...ins why the biologics provide a unique treatment option for psoriasis and psoriatic
arthritis. Cytovance® Biologics Announces the Company is Expanding - 0...